tbuckley/cabot-search huggingface dataset:
Enzyme replacement therapy with taliglucerase alfa: 36‐month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase
Authors: Gregory M. Pastores, Suma P. Shankar, Milan Petakov, Pilar Giraldo, Hanna Rosenbaum, Dominick J. Amato, Jeffrey Szer, Raul Chertkoff, Einat Brill‐Almon, Ari Zimran
Journal: American Journal of Hematology (2016)

Taliglucerase alfa is the first available plant cell-expressed human recombinant therapeutic protein. It is indicated for treatment of patients with type 1 Gaucher disease (GD) in adult and pediatric patients in several countries. Study PB-06-002 examined the safety and efficacy of taliglucerase alfa for 9 months in patients who previously received imiglucerase. The results of adult patients from Study PB-06-002 who continued receiving taliglucerase alfa in extension Study PB-06-003 for up to 36 months are reported here. Eighteen patients received at least one dose of taliglucerase alfa in Study PB-06-003; 10 patients completed 36 total months of therapy, and four patients who transitioned to commercial drug completed 30-33 months of treatment. In patients who completed 36 total months of treatment, mean percent (±standard error) changes from baseline/time of switch to taliglucerase alfa to 36 months were as follows: hemoglobin concentration, -1.0% (±1.9%; n = 10); platelet count, +9.3% (±9.8%; n = 10); spleen volume measured in multiples of normal (MN), -19.8% (±9.9%; n = 7); liver volume measured in MN, +0.9% (±5.4%; n = 8); chitotriosidase activity, -51.5% (±8.1%; n = 10); and CCL18 concentration, -36.5 (±8.0%; n = 10). Four patients developed antidrug antibodies, including one with evidence of neutralizing activity in vitro. All treatment-related adverse events were mild or moderate and transient. The 36-month results of switching from imiglucerase to taliglucerase alfa treatment in adults with GD provide further data on the clinical safety and efficacy of taliglucerase alfa beyond the initial 9 months of the original study. www.clinicaltrials.gov identifier NCT00705939. Am. J. Hematol. 91:661-665, 2016. © 2016 Wiley Periodicals, Inc.
EU exit would have a detrimental effect on the NHS, academics warn
Authors: Ingrid Torjesen
Journal: BMJ (2016)

Leaving the European Union (EU) would have an adverse impact on the NHS and the health of UK residents, a group of academics from the school of public health at Imperial College, London said in an article in the Journal of the Royal Society of Medicine .1 NHS England chief executive, Simon Stevens, has agreed with this view.

The group, led by Azeem Majeed, head of the department of primary care and public health at Imperial College, said that repercussions for the NHS and UK health would result from the impact of an EU exit on the economy. A Treasury analysis has estimated that tax receipts could be up to £36b a year lower after Brexit—equivalent to …
Effect of X Irradiation on the Growth of the Ehrlich Ascites Tumor&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;
Authors: László Révész
Journal: JNCI Journal of the National Cancer Institute (1955)

Effect of X Irradiation on the Growth of the Ehrlich Ascites Tumor László Révész László Révész Institute for Cell Research and Genetics, Karolinska Institutet, Stockholm, Sweden Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 15, Issue 6, June 1955, Pages 1691–1701, https://doi.org/10.1093/jnci/15.6.1691 Published: 01 June 1955 Article history Received: 03 November 1954 Published: 01 June 1955
Abstract IA06: Disregulation of lncRNAs helps drive Ewing sarcoma pathogenesis
Authors: Alejandro Sweet-Cordero
Journal: Cancer Research (2016)

Abstract Pediatric sarcomas are orphan diseases that cause significant morbidity and mortality in children, adolescents and young adults. Among the most intriguing pediatric sarcomas is Ewing sarcoma. The (11;22)(q24;q12) translocation, which leads to expression of EWS/FLI, is identified in 85% of Ewing sarcoma cases. Ewing sarcoma cells carrying this translocation have a strict dependency on its expression, suggesting that the translocation is a critical oncogenic event in this disease. Despite intensive investigation, the mechanisms through which EWS/FLI leads to oncogenesis are incompletely understood. Recent data indicates that two distinct mechanisms are involved. In one, EWS/FLI leads to gene activation by acting as a pioneer transcription factor at novel enhancers. In another, EWS/FLI forces the removal of ets binding factors from their established binding sites and acts as a transcriptional repressor. How these two diverse functions are orchestrated at a molecular level remains unclear. Given the widespread transcription of long non-coding RNAs and their emerging role in gene regulation, they are strong candidates for participation in the complex genetic rewiring program induced by EWS/FLI. We recently described the first lncRNA clearly regulated by EWS/FLI, (EWS-associated transcript 1, EWSAT1). Expression of EWS/FLI drives upregulation of EWSAT1 most likely by direct transcriptional regulation. EWSAT1 in turn plays a critical role in EWS/FLI-mediated gene repression, at least in part by interacting with the RNA binding protein hnRNPK. RNAseq analysis indicates that EWS/FLI regulates the expression of a large number of other lncRNAs in addition to EWSAT1. We have identified lnc659 (EWSAT2) as a second Ewing sarcoma-related transcript with functional relevance to Ewing pathogenesis. EWSAT2 is upregulated by expression of EWS/FLI and knock-down of EWSAT2 strongly decreases the proliferation of Ewing sarcoma cell lines in vitro and the oncogenicity of cell lines and patient-derived xenografts in vivo. Ongoing studies are directed at identifying the molecular mechanism of action of EWSAT1 and EWSAT2 as well as other lncRNAs in the pathogenesis of Ewing sarcoma. Citation Format: Alejandro Sweet-Cordero. Disregulation of lncRNAs helps drive Ewing sarcoma pathogenesis. [abstract]. In: Proceedings of the AACR Special Conference on Noncoding RNAs and Cancer: Mechanisms to Medicines ; 2015 Dec 4-7; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2016;76(6 Suppl):Abstract nr IA06.
CD11b<sup>+</sup>Gr-1<sup>+</sup>myeloid-derived suppressor cells reduce atherosclerotic lesion development in LDLr deficient mice
Authors: Amanda C. Foks, Gijs H.M. Van Puijvelde, Jolien Wolbert, Mara J. Kröner, Vanessa Frodermann, Thomas Van Der Heijden, Peter J. Van Santbrink, Louis Boon, Ilze Bot, Johan Kuiper
Journal: Cardiovascular Research (2016)

Myeloid-derived suppressor cells (MDSCs) form a heterogeneous population of cells composed of early myeloid progenitor cells and immature myeloid cells, which strongly suppress pro-inflammatory immune cells in inflammatory diseases. Currently, it is unknown whether MDSCs contribute to atherosclerosis, a chronic inflammatory disease in which accumulation of lipoproteins in the arterial wall activates the immune system causing abnormal vascular remodelling and vessel occlusion. Here, we investigated whether and how MDSCs contribute to the development of atherosclerosis. We show that MDSCs arise in the bone marrow of LDLr −/− mice during atherosclerosis and strongly suppress proliferation of T cells. Adoptive transfer of MDSCs into both female and male LDLr −/− mice fed a Western-type diet (WTD) ameliorates atherosclerosis with 35%. We observed a 54% reduction in adventitial T cells, and more specifically, MDSCs suppress Th1 and Th17 cells. In addition, treatment with MDSCs reduces circulating pro-atherogenic B2 cells. We found two subsets of MDSCs in the bone marrow of hypercholesterolemic mice, monocytic and granulocytic MDSCs (mo- and gr-MDSCs, respectively), of which the percentage of mo-MDSCs significantly increased during WTD feeding. Moreover, mo-MDSCs completely abolished splenocyte proliferation, whereas gr-MDSCs were unable to suppress proliferation. Mechanistically, we show that MDSCs from atherosclerotic mice suppress T cells in an IFN-γ- and nitric oxide-dependent manner, which is associated with the action of mo-MDSCs. This study demonstrates that MDSCs develop during atherosclerosis and reduce atherosclerosis via suppression of pro-inflammatory immune responses.
Increased 4R-Tau Induces Pathological Changes in a Human-Tau Mouse Model
Authors: Kathleen M. Schoch, Sarah L. DeVos, Rebecca L. Miller, Seung J. Chun, Michaela Norrbom, David F. Wozniak, Hana N. Dawson, C. Frank Bennett, Frank Rigo, Timothy M. Miller
Journal: Neuron (2016)
Prenatal Air Pollution Exposures, DNA Methyl Transferase Genotypes, and Associations with Newborn LINE1 and Alu Methylation and Childhood Blood Pressure and Carotid Intima-Media Thickness in the Children’s Health Study
Authors: Carrie V. Breton, Jin Yao, Josh Millstein, Lu Gao, Kimberly D. Siegmund, Wendy Mack, Lora Whitfield-Maxwell, Fred Lurmann, Howard Hodis, Ed Avol, Frank D. Gilliland
Journal: Environmental Health Perspectives (2016)

Background:Although exposure to ambient air pollutants increases cardiovascular disease risk in adults little is known about the effects of prenatal exposure. Genetic variation and epigenetic alterations are two mechanisms that may influence the effects of early-life exposures on cardiovascular phenotypes.Objectives:We investigated whether genetic and epigenetic variation modify associations between prenatal air pollution on markers of cardiovascular risk in childhood.Methods:We used linear regression analysis to investigate the associations between prenatal pollutants (PM2.5, PM10, NO2, O3), long interspersed nuclear elements (LINE1) and AluYb8 DNA methylation levels measured in newborn blood spot tests, and carotid intima-media thickness (CIMT) and blood pressure (BP) in 459 participants as part of the Children's Health Study. Interaction terms were also included to test for effect modification of these associations by genetic variation in methylation reprogramming genes.Results:Prenatal exposure to NO2 in the third trimester of pregnancy was associated with higher systolic BP in 11-year-old children. Prenatal exposure to multiple air pollutants in the first trimester was associated with lower DNA methylation in LINE1, whereas later exposure to O3 was associated with higher LINE1 methylation levels in newborn blood spots. The magnitude of associations with prenatal air pollution varied according to genotype for 11 SNPs within DNA methyltransferase 1 (DNMT1), DNA methyltransferase 3 Beta (DNMT3B), Tet methylcytosine dioxygenase 2 (TET2), and Thymine DNA glycosylase (TDG) genes. Although first-trimester O3 exposure was not associated with CIMT and systolic BP overall, associations within strata of DNMT1 or DNMT3B were observed, and the magnitude and the direction of these associations depended on DNMT1 genotypes.Conclusions:Genetic and epigenetic variation in DNA methylation reprogramming genes and in LINE1 retrotransposons may play important roles in downstream cardiovascular consequences of prenatal air pollution exposure.Citation:Breton CV, Yao J, Millstein J, Gao L, Siegmund KD, Mack W, Whitfield-Maxwell L, Lurmann F, Hodis H, Avol E, Gilliland FD. 2016. Prenatal air pollution exposures, DNA methyl transferase genotypes, and associations with newborn LINE1 and Alu methylation and childhood blood pressure and carotid intima-media thickness in the Children's Health Study. Environ Health Perspect 124:1905–1912; http://dx.doi.org/10.1289/EHP181
Absence of acquired tolerance to neuroleptics in schizophrenic patients
Authors: T Palmstierna, B Wistedt
Journal: American Journal of Psychiatry (1987)

Development of increased tolerance to neuroleptics was investigated in 38 neuroleptic-respondent schizophrenic patients. At 5- or 8-year follow-up, clinical global assessments were related to changes in neuroleptic doses. In 93% of the patients gradually increasing tolerance could be excluded.
Final Study Results of the Phase 3 Dasatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Trial (DASISION, CA180-056)
Authors: Jorge E. Cortes, Giuseppe Saglio, Michele Baccarani, Hagop M. Kantarjian, Jiří Mayer, Concepción Boqué, Neil P. Shah, Charles Chuah, Luis Casanova, Geetha Narayanan, Brigid Bradley-Garelik, George Manos, Andreas Hochhaus
Journal: Blood (2014)
Annie
Authors: Mitchell G Miglis
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP).
Authors: A. L. Cohn, T. Bekaii-Saab, J. C. Bendell, H. Hurwitz, M. Kozloff, N. Roach, H. Tezcan, S. Feng, A. Sing, A. Grothey
Journal: Journal of Clinical Oncology (2010)

3596 Background: BV (Avastin) prolongs progression free (PFS) and overall survival (OS) when added to chemotherapy (CT) in first- or second-line treatment (Tx) of mCRC. BRiTE, a prior OCS, provided information on BV clinical outcomes in almost 2,000 pts with mCRC receiving first-line BV. ARIES, a second OCS, includes mCRC pts receiving first- or second-line BV. Unlike BRiTE, ARIES collects specific dates of BV administration as well as other data allowing analyses of the impact of Tx patterns on safety and effectiveness. Methods: Pts with mCRC receiving first-line or second-line CT + BV were enrolled. No Tx regimens or assessments were protocol specified. Data were collected prospectively at baseline (BL) and quarterly. The first-line pts who experienced progressive disease (PD) were grouped as: No post-PD Tx, post-PD Tx without BV (No BBP) and BBP (only pts with > 1 post PD BV dose). Survival beyond first PD (SBP), OS and PFS were described for the 3 pt groups. Relevant BL and on-study variables, including BBP, were analyzed by Cox model to identify independent effects on SBP. BV targeted adverse events (AEs) are described for the 3 pt groups, pre and post PD. Results: 1,546 first-line mCRC pts enrolled; 1097 pts had PD as of the data cutoff (9/21/09): No post-PD Tx (127), No BBP (417) and BBP (539). BL characteristics were similar to pts in BRiTE. The median OS, PFS and SBP were 24.7, 10.1 and 12.6 mo, respectively, for the entire cohort. BL and post BL factors were similar between the BBP and No-BBP groups. Median SBP = 5.2, 8.5 and 16.3 mo in the No post-PD Tx, No-BBP and BBP groups, respectively. Multivariate analyses confirmed that BBP was strongly and independently associated with improved SBP (HR = 0.41, 95% CI 0.34-0.49, p < 0.001). BV targeted AEs for the first-line cohort were similar to those in BRiTE. Rates of BV targeted AEs in BBP pts were low: GI perforation 0.2%, arteriothromboembolic events 1.9%, bleeding 3.7%. Conclusions: ARIES first-line mCRC pt outcomes were consistent with previous reports from BRiTE. ARIES BBP analyses affirm the BRiTE BBP data and the suggestion that continued suppression of VEGF is an important component of improving outcomes for mCRC pts. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genentech Amgen, AstraZeneca, Bayer, Genentech, Roche, sanofi-aventis Roche Genentech, Roche, sanofi-aventis Amgen, Bayer, Bristol-Myers Squibb, Genentech, Pfizer, Roche, sanofi-aventis, Standard Research Only Genentech
WITHDRAWN: Transforming berberine into its intestine absorbable form by gut microbiota
Authors: Yan Wang, Ru Feng, Jia-Wen Shou, Zhen-Xiong Zhao, Jian-Dong Jiang
Journal: Asian Journal of Pharmaceutical Sciences (2015)

This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.
Performance of DSM-5 Persistent Complex Bereavement Disorder Criteria in a Community Sample of Bereaved Military Family Members
Authors: Stephen J. Cozza, Joscelyn E. Fisher, Christine Mauro, Jing Zhou, Claudio D. Ortiz, Natalia Skritskaya, Melanie M. Wall, Carol S. Fullerton, Robert J. Ursano, M. Katherine Shear
Journal: American Journal of Psychiatry (2016)

The purpose of this article was to examine the accuracy of DSM-5 proposed criteria for persistent complex bereavement disorder in identifying putative cases of clinically impairing grief and in excluding nonclinical cases. Performance of criteria sets for prolonged grief disorder and complicated grief were similarly assessed.Participants were family members of U.S. military service members who died of any cause since September 11, 2001 (N=1,732). Putative clinical and nonclinical samples were derived from this community sample using cutoff scores from the Inventory of Complicated Grief and the Work and Social Adjustment Scale. Items from a self-report grief measure (Complicated Grief Questionnaire) were matched to DSM-5 persistent complex bereavement disorder, prolonged grief disorder, and complicated grief criteria. Endorsed items were used to identify cases.Criteria sets varied in their ability to identify clinical cases. DSM-5 persistent complex bereavement disorder criteria identified 53%, prolonged grief disorder criteria identified 59%, and complicated grief criteria identified more than 90% of putative clinical cases. All criteria sets accurately excluded virtually all nonclinical grief cases and accurately excluded depression in the absence of clinical grief.The DSM-5 persistent complex bereavement disorder criteria accurately exclude nonclinical, normative grief, but also exclude nearly half of clinical cases, whereas complicated grief criteria exclude nonclinical cases while identifying more than 90% of clinical cases. The authors conclude that significant modification is needed to improve case identification by DSM-5 persistent complex bereavement disorder diagnostic criteria. Complicated grief criteria are superior in accurately identifying clinically impairing grief.
TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer
Authors: Anna C. Groner, Laura Cato, Jonas de Tribolet-Hardy, Tiziano Bernasocchi, Hana Janouskova, Diana Melchers, René Houtman, Andrew C.B. Cato, Patrick Tschopp, Lei Gu, Andrea Corsinotti, Qing Zhong, Christian Fankhauser, Christine Fritz, Cédric Poyet, Ulrich Wagner, Tiannan Guo, Ruedi Aebersold, Levi A. Garraway, Peter J. Wild, Jean-Philippe Theurillat, Myles Brown
Journal: Cancer Cell (2016)
e-Monitoring of Asthma Therapy to Improve Compliance in children (e-MATIC): a randomised controlled trial
Authors: Erwin C. Vasbinder, Lucas M.A. Goossens, Maureen P.M.H. Rutten-van Mölken, Brenda C.M. de Winter, Liset van Dijk, Arnold G. Vulto, Ellen I.M. Blankman, Nordin Dahhan, Monique T.M. Veenstra-van Schie, Florens G.A. Versteegh, Bart H.M. Wolf, Hettie M. Janssens, Patricia M.L.A. van den Bemt
Journal: European Respiratory Journal (2016)

Real-time medication monitoring (RTMM) is a promising tool for improving adherence to inhaled corticosteroids (ICS), but has not been sufficiently tested in children with asthma. We aimed to study the effects of RTMM with short message service (SMS) reminders on adherence to ICS, asthma control, asthma-specific quality of life and asthma exacerbation rate; and to study the associated cost-effectiveness. In a multicentre, randomised controlled trial, children (aged 4–11 years) using ICS were recruited from five outpatient clinics and were given an RTMM device for 12 months. The intervention group also received tailored SMS reminders, sent only when a dose was at risk of omission. Outcome measures were adherence to ICS (RTMM data), asthma control (childhood asthma control test questionnaire), quality of life (paediatric asthma quality of life questionnaire) and asthma exacerbations. Costs were calculated from a healthcare and societal perspective. We included 209 children. Mean adherence was higher in the intervention group: 69.3% versus 57.3% (difference 12.0%, 95% CI 6.7%–17.7%). No differences were found for asthma control, quality of life or asthma exacerbations. Costs were higher in the intervention group, but this difference was not statistically significant. RTMM with tailored SMS reminders improved adherence to ICS, but not asthma control, quality of life or exacerbations in children using ICS for asthma.
Cancer from mineral oil.
Authors: A Wannag
Journal: BMJ (1969)

PointersPrimary Amoebic Meningoencephalitis: Th usually fatal disease, caused by-free-living saprt phytic amoebae, probably occurs in Britain, fc two examples were found during the review c specimens in a London pathology museum, or dated 1909 reputedly from Essex, the secon dated 1937 from Belfast (p.449).Intermittent Corticotrophin in Asthma: In provement in respiratory function lasted longe than the enhancement of adrenocortical activit3 as judged by plasma cortisol levels (p.455).Alcoholism and Blood Group: A controlle investigation of ABO blood group and secreto status in 1,000 alcoholics shows an unexplaine increase in group A non-secretors (p.457).Response to Gastric Stimulants: Impairment o response to gastric stimulants such as penta gastrin can occur after repeated testing (p.459) Haemolytc Anaemia in Pregnancy: Pred nisolone was effective in controlling haemolysi in 5 of 6 pregnant Nigerians with severe haemo lytic anaemia (p.461).Fatal Appendicitis in Children: Analysis o the 204 deaths in England and Wales during th five-year period 1963-7 (p.466).Chronic Bronchitis: Comparative trial of tri methoprim-sulphamethoxazole and ampicillir suggests that the trimethoprim mixture is useful and safe (p.470).Hb H Disease in Pregnancy: Managemen (p.473).Epilepsy in Childhood: Current Practice article on drug treatment (p.475).
Stereotactic Ablative Radiotherapy for Non–Small Cell Lung Cancer: Rationale and Outcomes
Authors: Puneeth Iyengar, Robert D Timmerman
Journal: Journal of the National Comprehensive Cancer Network (2012)

Stereotactic ablative radiotherapy (SABR), also known in older reports as stereotactic body radiation therapy, represents an evolving and expanding radiation treatment option for many forms of local malignancy, from primary tumors to metastatic and recurrent disease. It involves the precise delivery of higher doses of external-beam radiation per treatment over a shortened treatment course compared with traditional regimens. SABR has become the standard of care for patients with medically inoperable early-stage non–small cell lung cancer (NSCLC) and is becoming a more viable option for surgical candidates with early-stage primary NSCLCs who prefer noninvasive modalities of treatment. Although SABR is being used for the treatment of primary and metastatic disease in many sites of the body, such as the central nervous system, liver, pancreas, spine metastases, and isolated nodal disease in the mediastinum and abdomen, this article focuses on treatment of NSCLC in the thorax. Specifically, this review provides the rationale, evidence, and indications for treating early-stage lung cancers with SABR.